Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (5392)	6/20/1999 6:38:00 PM
From: BelowTheCrowd	Respond to of 5736

> the agreement grants DO negotiation rights for international marketing and distribution of the Company's monitoring system for the potential retail market and consumer home healthcare market where the test is not administered by a healthcare professional, subject to further required regulatory clearances for commericial use...... < Not sure why you keep emphasizing this one. They have no permission to sell to those markets, and haven't announced any intentions to apply for further approvals. It's just boilerplate which is unlikely to have any material impact anytime soon. > the DO Purchase Price for each of the first two Performance Years shall be equal to the higher of (i) sixty percent (60%) of the Invoice Price for the Products or (ii) the Minimum Transfer Price for each Product set forth on Attachment A hereto... (b) The DO Purchase Price after the first two Performance Years shall be equal to the higher of (i) fifty percent (50%) of the Invoice Price for the Products... < Doesn't tell us much, does it. We don't know what DO is going to actually sell these things for ("list price" doesn't count) and we definitely don't know how much it costs to make them. Bottom line is that we still don't know if they can make money selling them. The current arrangement could very well result in ongoing losses... mg

To: JanyBlueEyes who wrote (5392)	6/20/1999 7:39:00 PM
From: musicman	Read Replies (1) \| Respond to of 5736

Dear Janybird & Spunky 71: What is your opinion of the 8K? Is it what you hoped for? Where do you think the stock is going from here-short term/long term? Thanks musicman

To: JanyBlueEyes who wrote (5392)	6/20/1999 8:10:00 PM
From: musicman	Respond to of 5736

To: JanyBlueEyes who wrote (5392)	6/20/1999 9:24:00 PM
From: BDR	Read Replies (1) \| Respond to of 5736

< hospital market, the non-consumer home healthcare market (in which the test is administered solely by a healthcare professional), the pediatrician, office market and clinics within all such markets> Is the Tlc Bilitest been deemed exempt from CLIA? The reason I ask is that those offices that are not now licensed under CLIA to do a range of more complex in-office testing will need to apply for permission, pay a fee and be subject to oversight unless the test is determined to be exempt (e.g. dipstick urinalysis and microscopic examination of urinary sediment are exempt "simple" tests). Many physician offices have gotten out of the business of doing all but the simplest, and in some cases all, in-office lab work because of the additional expense and bureaucratic hassle.

To: JanyBlueEyes who wrote (5392)	6/21/1999 12:58:00 PM
From: Marconi	Read Replies (1) \| Respond to of 5736

Hello Janybird: A 60% 'discount' explains why the $3K devices previously are now listed at $5K for the most part. Nothing has changed. Do you have any evidence there is a $2K enhancement to the devices that has not been disclosed? I see nothing. Looks like status quo to me for CCSI. I will comb through the 8K this week, looking to improve my positions for better gains. I remain short. Best regards, m